drugset / Trial / NCT00020267

Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00020267

Treatment

Summary

RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer that has not responded to previous therapy.

Timeline

Start
2000-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject MAGE-12 peptide vaccine Unknown Subcutaneous
Background aldesleukin Protein / enzyme biologic Intravenous
Background incomplete Freund's adjuvant Other / unclassified Subcutaneous